Risk factors
Precigen (PGEN) risk factors
Item 1A of every Precigen, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors58 risks9 new9 dropped14 reworded
Precigen transitioned to a commercial-stage company following FDA approval of Papzimeos for RRP, securing $125.0 million in debt financing and scaling up launch and manufacturing risks.
Filed Mar 25, 2026 - FY2024 10-K risk factors58 risks
Substantial doubt about going concern given $2.1B accumulated deficit and reliance on PRGN-2012 for RRP.
Filed Mar 19, 2025